Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

BACKGROUND: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure (HF) and cardiomyopathy (CM). However, clinical trials may underestimate HF/CM risk because they enroll younger subjects with fewer...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Ezaz, Ghideon, Long, Jessica B., Gross, Cary P., Chen, Jersey
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Blackwell Publishing Ltd 2014
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959671/
https://ncbi.nlm.nih.gov/pubmed/24584736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.113.000472
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia